Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 4,148 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $65.71, for a total transaction of $272,565.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven J. Kafka also recently made the following trade(s):

  • On Tuesday, January 2nd, Steven J. Kafka sold 157 shares of Foundation Medicine stock. The stock was sold at an average price of $64.00, for a total transaction of $10,048.00.

Foundation Medicine Inc (NASDAQ FMI) traded down $0.60 during trading on Friday, hitting $66.35. 89,600 shares of the stock traded hands, compared to its average volume of 289,267. The company has a market cap of $2,420.00, a price-to-earnings ratio of -14.84 and a beta of -0.01. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a 12-month low of $17.50 and a 12-month high of $74.30.

Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The company had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. During the same quarter last year, the business posted ($0.90) EPS. The firm’s revenue for the quarter was up 45.0% on a year-over-year basis. equities analysts forecast that Foundation Medicine Inc will post -4.44 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in FMI. Lord Abbett & CO. LLC lifted its holdings in Foundation Medicine by 146.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after buying an additional 343,770 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in Foundation Medicine during the 3rd quarter valued at about $13,299,000. State Street Corp lifted its holdings in Foundation Medicine by 124.2% during the 2nd quarter. State Street Corp now owns 526,775 shares of the company’s stock valued at $20,947,000 after buying an additional 291,815 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Foundation Medicine by 8.2% during the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after buying an additional 47,843 shares in the last quarter. Finally, Quantitative Investment Management LLC bought a new stake in Foundation Medicine during the 2nd quarter valued at about $1,824,000. Institutional investors own 32.68% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Foundation Medicine from a “buy” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub lowered shares of Foundation Medicine from a “buy” rating to a “hold” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $45.33.

ILLEGAL ACTIVITY NOTICE: “Foundation Medicine Inc (FMI) COO Sells $272,565.08 in Stock” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://theolympiareport.com/2018/01/19/foundation-medicine-inc-fmi-coo-sells-272565-08-in-stock.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.